1. HDACs class I, II, IV mutations in human cancer
Figure 1 from Ceccacci and Minucci
British Journal of Cancer Advance Online Publication
23 February 2016 doi: /bjc
Several approaches exist to target Eph receptors. Kinase inactivating strategies include kinase inhibitors or blocking peptides or antibodies. Kinase activating strategies include ligand stimulation, activating antibodies or ligand peptide mimetics Strategies to deliver toxic payloads following receptor activation and internalisation include coupling of cytotoxic agents or radionuclides to Eph monoclonal antibodies.
© 2016 Cancer Research UK.